Inflammatory myofibroblastic tumor (IMT) is a neoplasm characterized by the proliferaton of myofibroblasts with the infiltration of inflammatory cells. There is no standard treatment for patients with recurrent or metastatic IMT. We describe here a patient with hyper-progressive IMT with an anaplastic lymphoma kinase (ALK) fusion gene that dramatically responded to alectinib without adverse events. His dramatic and enduring response supports the observation that alectinib may be considered a good treatment option for rare aggressive ALK-positive tumors.
Keywords: alectinib; anaplastic lymphoma kinase; inflammatory myofibroblastic tumor.
© The Author 2017. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: [email protected].